

Hypertension Evaluation Project III

Submission date 31/10/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/11/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 31/12/2020	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Hans Wilhelm Hoepp

Contact details
Kerpener Str. 62
Cologne
Germany
50937
-
hw.hoepp@uni-koeln.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
3

Study information

Scientific Title

Hypertension Evaluation Project III

Acronym

HEP III

Study objectives

Innovative ways for dissemination of guidelines are superior to traditional ways.

Ethics approval required

Old ethics approval format

Ethics approval(s)

All participants took part voluntarily and the interventions were optional therefore ethics approval was not necessary.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Quality of life

Participant information sheet

Health condition(s) or problem(s) studied

Hypertension

Interventions

1. Guideline in print
2. Interactive guideline
3. Expert seminars
4. Control group

The intervention groups were 3825 physicians for the expert seminars and always 1500 for the guideline in print, the interactive guideline and the control group. The medium follow-up time after intervention was approximately six months.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Difference in guideline awareness between trained physicians and the control group.

Secondary outcome measures

Overall guideline awareness.

Overall study start date

01/01/2004

Completion date

31/03/2005

Eligibility

Key inclusion criteria

Participants of HEP I-trial: In the HEP-I trial we explored the guideline awareness of 24899 German physicians, including all internists, cardiologists and 22% of general practitioners in a nationwide survey. The data is already published (see <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11677375>)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

8325

Total final enrolment

3825

Key exclusion criteria

See inclusion criteria.

Date of first enrolment

01/01/2004

Date of final enrolment

31/03/2005

Locations

Countries of recruitment

Germany

Study participating centre
Kerpener Str. 62
Cologne
Germany
50937

Sponsor information

Organisation

University of Cologne (Germany)

Sponsor details

Koeln Fortune Program
Faculty of Medicine
Kerpener Str. 62
Cologne
Germany
50937

-

t.hensler@uni-koeln.de

Sponsor type

University/education

Website

<http://www.uni-koeln.de/index.e.html>

ROR

<https://ror.org/00rcxh774>

Funder(s)

Funder type

University/education

Funder Name

University of Cologne (Germany) - Koeln Fortune Program, Faculty of Medicine

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/06/2008	31/12/2020	Yes	No